Letters to "Pharma Sis" to Cut EpiPen Price to Improve Goodwill Will Fall on a Tin Ear | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Well, congratulations,Mylan CEO Heather Bresch. You are the new Martin Shkreli, says Ed Silverman, author of Pharmalot.

 

You told CNBC that “we have fought night and day to bring products into the marketplace at affordable prices.” Well, no, you didn’t.

 

As a result, the battle over EpiPen pricing is now the latest proxy for the wider national discussion over corporate profits and affordable health care.

 

To prevent another EpiPen controversy, the government should step in

It’s not too late, though, for you to undo some of the damage. Wells Fargo analyst David Maris suggested you should lower the price to where it was two or three years ago and offer to reimburse families who purchased EpiPen during that time for their out-of-pocket costs. That’s a good idea.

 

Yes, such moves will cost you. But goodwill also has value. And the cost of belatedly displaying empathy may be much less than any laws that emerge as a result of the increasing skirmishes over drug costs.

 

You may think you can ride out the storm, Heather, but what if you’re wrong?